Second death triggers hold on Astellas' $3B gene therapy biotech's lead program, raising fresh concerns about AAV
Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
